Unknown molecular targets involved in intestinal cholesterol absorption and hepatic de novo cholesterol synthesis

This entry refers to a descriptive classification of molecular targets that regulate systemic cholesterol levels through two primary pathways: the absorption of dietary and biliary cholesterol in the small intestine and the endogenous production of cholesterol in the liver. Historically, several potent lipid-lowering agents were developed based on their physiological effects on these pathways before their specific protein targets were identified. For example, the drug ezetimibe was known to inhibit intestinal cholesterol absorption for years before its primary target, Niemann-Pick C1-Like 1 (NPC1L1), was discovered in 2004. Similarly, various natural products and experimental compounds are often described by their dual inhibitory effects on both intestinal absorption and hepatic de novo synthesis, even when the exact molecular interactions remain uncharacterized. These targets are critical in the management of hypercholesterolemia and the prevention of cardiovascular disease, as they collectively determine the pool of cholesterol available for lipoprotein assembly and circulation.

Other names

Cholesterol absorption and synthesis targetsIntestinal cholesterol absorption and hepatic de novo cholesterol synthesis targets

Inhibition of sterol transporters in the intestinal brush border and inhibition of rate-limiting enzymes in the mevalonate pathway.